A5032165812- Diabetes Management and Research
- Diabetes and associated disorders
- Pancreatic function and diabetes
- Diabetes Treatment and Management
- Cystic Fibrosis Research Advances
- COVID-19 Clinical Research Studies
- Diabetes Management and Education
- Mobile Health and mHealth Applications
- Electrolyte and hormonal disorders
- Immunodeficiency and Autoimmune Disorders
- Chronic Disease Management Strategies
- Diet, Metabolism, and Disease
- Obesity and Health Practices
- Diet and metabolism studies
- Pharmaceutical studies and practices
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Neuroendocrine Tumor Research Advances
- Neuroscience and Music Perception
- SARS-CoV-2 and COVID-19 Research
- Coronary Artery Anomalies
- Vaccine Coverage and Hesitancy
- Congenital Heart Disease Studies
- Kawasaki Disease and Coronary Complications
- Childhood Cancer Survivors' Quality of Life
- COVID-19 Impact on Reproduction
Children's Hospital of Philadelphia
2022-2025
University of Pennsylvania
2022-2025
Philadelphia University
2024
Buckinghamshire Healthcare NHS Trust
2024
Children's National
2020-2023
George Washington University
2020-2023
Boston Children's Hospital
2019-2021
Queen Elizabeth Hospital
2021
Houston Methodist Sugar Land Hospital
2020
Alfred I. duPont Hospital for Children
2016
Background: We assessed changes in glycemic control and person-reported outcome measures (PROMs) with t:slim X2 insulin pump Control-IQ technology use among historically minoritized youth who are least likely to access hybrid closed loop (HCL) technology. Methods: This single-arm, prospective pilot study enrolled 15 publicly insured, pump-naïve, non-Hispanic Black ages 6 <21 years type 1 diabetes hemoglobin A1c (HbA1c) ≥10% a 6-month of HCL use. The primary was absolute change time range...
Purpose The purpose of the study was to identify most common reasons for and timing continuous glucose monitoring (CGM) attrition in youth with type 1 diabetes (T1DM). Methods This single center retrospective chart review included T1DM <22 years seen between November 1, 2021, October 31, 2022. Data were gathered from CGM cloud-based software electronic medical record. Results Among 2663 youth, 88.3% (n = 2351) actively used CGM, 5.9% 311) had attrition. Those who discontinued older (17.0...
The impact of the COVID-19 pandemic on incidence pediatric type 1 (T1D) and 2 diabetes (T2D) severity presentation at diagnosis is unclear.A retrospective comparison 737 youth diagnosed with T1D T2D during initial 12 months in preceding years was conducted a tertiary care center.Incident cases rose from 152 to 158 before (3.9% increase) 182 (15.2% increase). prevalence diabetic ketoacidosis (DKA) increased over 3 (41.4%, 51.9%, 57.7%, p = 0.003); severe DKA as compared (16.8% vs. 28%,...
Diabetes is a risk factor for poor COVID-19 outcomes, but pediatric patients with type 1 diabetes are poorly represented in current studies. T1D Exchange coordinated US registry. Forty-six centers submitted cases laboratory confirmed COVID-19. Associations between clinical factors and hospitalization were tested Fisher's Exact Test. Logistic regression was used to calculate odds ratios hospitalization. Data from 266 previously established aged <19 years reported. Diabetic ketoacidosis (DKA)...
Pivotal trials of diabetes technologies have demonstrated glycemic improvements; however, these include patients limited diversity and ranges control. We assessed changes in control during the first 90 days Omnipod 5 use a real-world cohort youth with type 1 (T1D).
Abstract Objective Glycemic outcomes in youth with type 1 diabetes (T1D) the United States using two most common automated insulin delivery (AID) systems, Insulet Omnipod 5 (OP5) and Tandem Control IQ (CIQ), have not been compared. We performed first head-to-head analysis of changes glycemic metrics among initiating AID. Methods This single center, retrospective study included &lt;21 years T1D, who started OP5 or CIQ between 1/2020 12/2023, had ≥70% CGM active time. 14-day baseline...
There have been tremendous advances in diabetes technology the last decade. Continuous glucose monitors (CGM), insulin pumps, and automated delivery (AID) systems aim to improve glycemic control while simultaneously decreasing burden of management. Although technologies shown decrease both hypoglycemia hyperglycemia health-related quality life individuals with type 1 diabetes, impact these devices cystic fibrosis-related (CFRD) is less clear. are unique aspects CFRD, including different...
Background: Recent data demonstrating a lack of improvement in average hemoglobin A1c levels despite the increased use insulin pumps and continuous glucose monitors (CGMs) suggest that patients are not using these technologies optimally. Suboptimal provider understanding devices may be contributing factor. Methods: We sought to assess fellows' knowledge, attitudes, practices regarding CGMs mixed-methods survey. polled 42 pediatric endocrinology fellows 69 attending physicians items on...
Background: Diabetes technologies are associated with improvements in glycemic control and health-related quality of life among people type 1 diabetes (T1D). Use perceptions continuous glucose monitors (CGM) insulin pumps within the cystic fibrosis (CF) community have not been well studied. Methods: A 30-item online survey addressing fibrosis-related (CFRD) diagnosis, CGM pump use, was sent to a CF group, including (pwCF) parents children (cwCF). Results: The response rate 11% (n = 120; 83...
There are marked inequities in clinical outcomes and rates of diabetes technology use among youth with type 1 (T1D). The quantitative data from our mixed methods cohort study identified significant improvements glycaemia quality life participants. We aimed to qualitative provide further insight into findings the setting underlying health disparities.
Spontaneous episodes of hypoglycemia can occur in people with cystic fibrosis (CF) without diabetes, who are not on glucose lowering medications. CF could both the fasting or postprandial state (reactive hypoglycemia). The pathophysiology is thought to be related malnutrition and increased energy expenditure setting inflammation acute infections. Reactive due impaired first phase insulin release response a load, followed by delayed extended second secretion; ineffective counterregulatory...
This article describes the evolution of Type 1 Diabetes Exchange Quality Improvement Collaborative (T1DX-QI) and provides insight into development growth a successful type diabetes quality improvement (QI) program. Since its inception 8 years ago, collaborative has expanded to include centers across United States with varying levels QI experience, while simultaneously achieving many tangible improvements in care. These successes underscore importance learning health systems, data-sharing,...
We explored the impact of TeKnO T1D, an online, case-based, spaced education curriculum about insulin pump and continuous glucose monitor (CGM) use in pediatric type 1 diabetes management.Pediatric endocrinology fellows (n = 64) were randomized to receive educational focused on either pumps or CGMs. Fellows received interactive questions twice weekly via email mobile app. Median time completion was 76.5 days. The primary outcome change knowledge as measured by performance multiple-choice...
Objective: To describe sociodemographic and parent psychosocial characteristics associated with patterns of continuous glucose monitor (CGM) use across the first 18 months post-type 1 diabetes (T1D) diagnosis among young children. Methods: One hundred fifty-seven parent-child dyads enrolled in a behavioral intervention for parents children (1-6 years) newly diagnosed T1D. Parents reported on baseline functioning; child CGM was assessed at five time points during post-diagnosis. Results: Most...